应交易所要求,美/港股行情延时15分钟展示,下载APP即可免费查看实时行情。
关闭
BBTX Bambusa Therapeutics
已收盘 10-30 16:00:00 EDT
14.99
-1.01
-6.31%
盘后
14.21
-0.78
-5.20%
18:44 EDT
最高
15.66
最低
13.60
成交量
220.01万
今开
14.88
昨收
16.00
日振幅
12.88%
总市值
7.46亿
流通市值
1.41亿
总股本
4,976万
成交额
3,204万
换手率
23.47%
流通股本
937.50万
市净率
--
ROE
--
每股收益
0.00
52周最高
--
52周最低
--
市盈率
--
股息
--
股息收益率
--
ROA
--
分时
五日
日K
周K
月K
数据加载中...
北京优虎网络科技有限公司
资讯
新帖
简况
美股异动 | Bambusa Therapeutics(BBTX.US)登陆美股市场 股价跌超8%
智通财经 · 00:03
美股异动 | Bambusa Therapeutics(BBTX.US)登陆美股市场 股价跌超8%
中点定价、超募发行:Bambusa (BBTX.US) IPO融资1.69亿美元,市值锁定8.15亿
智通财经 · 10-30 10:30
中点定价、超募发行:Bambusa (BBTX.US) IPO融资1.69亿美元,市值锁定8.15亿
免疫学与炎症生物科技公司Bambusa(BBTX.US)IPO定价15-17美元/股 拟筹资1.5亿美元
智通财经 · 10-27
免疫学与炎症生物科技公司Bambusa(BBTX.US)IPO定价15-17美元/股 拟筹资1.5亿美元
暂无数据
公司概况
公司名称:
Bambusa Therapeutics
所属市场:
NASDAQ
上市日期:
--
主营业务:
Bambusa Therapeutics, Inc.于2024年3月14日在特拉华州注册成立,是一家临床阶段的生物制药公司,开发下一代长效精准双特异性抗体,旨在重新定义免疫学和炎症方面的护理标准,并提高患者的生活质量。其主要候选产品BBT001是一种靶向IL-4Rα和IL-31的长效双特异性抗体,旨在同时解决核心2型炎症和慢性瘙痒,目前正在针对中重度特应性皮炎和慢性自发性荨麻疹进行临床试验评估。
发行价格:
--
{"stockData":{"symbol":"BBTX","market":"US","secType":"STK","nameCN":"Bambusa Therapeutics","latestPrice":14.99,"timestamp":1793390400000,"preClose":16,"halted":0,"volume":2200121,"hourTrading":{"tag":"盘后","latestPrice":14.21,"preClose":14.99,"latestTime":"18:44 EDT","volume":1649,"amount":23422.145,"timestamp":1793400242374,"change":-0.78,"changeRate":-0.052035,"amplitude":0.052702},"delay":0,"changeRate":-0.06312499999999999,"floatShares":9375000,"shares":49761899,"eps":0,"marketStatus":"已收盘","change":-1.01,"latestTime":"10-30 16:00:00 EDT","open":14.88,"high":15.66,"low":13.6,"amount":32038846.239630997,"amplitude":0.12875,"askPrice":0,"askSize":0,"bidPrice":0,"bidSize":0,"shortable":3,"etf":0,"ttmEps":0,"tradingStatus":0,"nextMarketStatus":{"tag":"盘前交易","tradingStatus":1,"beginTime":1793610000000},"marketStatusCode":5,"adr":0,"listingDate":1793332800000,"exchange":"NASDAQ","adjPreClose":16,"postHourTrading":{"tag":"盘后","latestPrice":14.21,"preClose":14.99,"latestTime":"18:44 EDT","volume":1649,"amount":23422.145,"timestamp":1793400242374,"change":-0.78,"changeRate":-0.052035,"amplitude":0.052702},"volumeRatio":0},"requestUrl":"/m/hq/s/BBTX/tweets","defaultTab":"tweets","newsList":[{"id":"2679688246","title":"美股异动 | Bambusa Therapeutics(BBTX.US)登陆美股市场 股价跌超8%","url":"https://stock-news.laohu8.com/highlight/detail?id=2679688246","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2679688246?lang=zh_cn&edition=full","pubTime":"2026-10-31 00:03","pubTimestamp":1793376223,"startTime":"0","endTime":"0","summary":"智通财经APP获悉,周五,Bambusa Therapeutics登陆美股市场,截至发稿,该股跌超8%,报14.685美元。IPO价格为16美元。Bambusa Therapeutics是一家总部位于美国波士顿的临床阶段生物制药公司,专注于开发治疗免疫系统及炎症性疾病的新一代长效双特异性抗体药物。公司的主要在研药物BBT001用于治疗特应性皮炎(湿疹)、慢性自发性荨麻疹等皮肤疾病;另一款候选药物BBT002则主要针对哮喘、慢性阻塞性肺病及慢性鼻窦炎伴鼻息肉等炎症性疾病。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1516689.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK4139","BK4007","BBTX","LENZ","BK4539"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2679252478","title":"中点定价、超募发行:Bambusa (BBTX.US) IPO融资1.69亿美元,市值锁定8.15亿","url":"https://stock-news.laohu8.com/highlight/detail?id=2679252478","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2679252478?lang=zh_cn&edition=full","pubTime":"2026-10-30 10:30","pubTimestamp":1793327430,"startTime":"0","endTime":"0","summary":"智通财经APP获悉,专注于皮肤病和自身免疫疾病的早期生物科技公司Bambusa Therapeutics Inc.通过扩大规模的美国首次公开募股融资1.689亿美元,发行价定在推介区间的中点。以IPO发行价计算,按文件中列出的流通股数量,Bambusa的市值为8.15亿美元。截至6月底,Bambusa持有现金及等价物7150万美元。Bambusa预计其股票将于周五在纳斯达克全球精选市场挂牌交易,股票代码为BBTX。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1515853.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["IPOS","BBTX","BK4127","REDS","FRHC","KCE"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2678236281","title":"免疫学与炎症生物科技公司Bambusa(BBTX.US)IPO定价15-17美元/股 拟筹资1.5亿美元","url":"https://stock-news.laohu8.com/highlight/detail?id=2678236281","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2678236281?lang=zh_cn&edition=full","pubTime":"2026-10-27 15:10","pubTimestamp":1793085040,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.zhitongcaijing.com/immediately.html?type=usstock","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"live_zhitongcaijing","symbols":["UUP","LNGR","IBBJ","MEDX","BK4581","IEIH","AGNG","XBI","BBTX","GDOC","UDN","BK4585","BK4588","SYNB","IPOS"],"isVideo":false,"video":null,"gpt_icon":0}],"profile":{"websiteUrl":"http://www.bambusatx.com","compareEarnings":[{"period":"1week","weight":0.0071},{"period":"1month","weight":0.0068},{"period":"3month","weight":0.0299},{"period":"6month","weight":0.0676},{"period":"1year","weight":0.1192},{"period":"ytd","weight":0.1282}],"compareStock":{"symbol":"SPY","name":"标普500ETF"},"description":"Bambusa Therapeutics, Inc.于2024年3月14日在特拉华州注册成立,是一家临床阶段的生物制药公司,开发下一代长效精准双特异性抗体,旨在重新定义免疫学和炎症方面的护理标准,并提高患者的生活质量。其主要候选产品BBT001是一种靶向IL-4Rα和IL-31的长效双特异性抗体,旨在同时解决核心2型炎症和慢性瘙痒,目前正在针对中重度特应性皮炎和慢性自发性荨麻疹进行临床试验评估。","exchange":"NASDAQ","name":"Bambusa Therapeutics","nameEN":"Bambusa Therapeutics"},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"isLaohu8Offline":false,"tenantId":"TBCN","deviceId":"web-server-community-laohu8-v3","version":"4.52.0","shortVersion":"4.52.0","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"Bambusa Therapeutics(BBTX)_个股概要_股票价格_最新资讯_行情走势_历史数据","description":"美港股上老虎。老虎社区提供Bambusa Therapeutics(BBTX)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","keywords":"Bambusa Therapeutics,BBTX,Bambusa Therapeutics股票,Bambusa Therapeutics股票老虎,Bambusa Therapeutics股票老虎国际,Bambusa Therapeutics行情,Bambusa Therapeutics股票行情,Bambusa Therapeutics股价,Bambusa Therapeutics股市,Bambusa Therapeutics股票价格,Bambusa Therapeutics股票交易,Bambusa Therapeutics股票购买,Bambusa Therapeutics股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"Bambusa Therapeutics(BBTX)_个股概要_股票价格_最新资讯_行情走势_历史数据","og_description":"美港股上老虎。老虎社区提供Bambusa Therapeutics(BBTX)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","og_image":"https://static.tigerbbs.com/a0b84b8debbbce3b4440f7fdd5eed2e7"}}}